Key Factors in Selecting IL-23p19 Inhibitors for Treating Inflammatory Bowel Disease

Overview

Selective IL-23p19 inhibitors—Risankizumab, Mirikizumab, and Guselkumab—have demonstrated favorable efficacy and safety in moderate-to-severe Crohn’s disease and ulcerative colitis. Clinical decision-making involves considering patient preferences, disease phenotype, comorbidities, and prior therapy exposure to optimize personalized treatment.

Background

Inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC), is driven by immune dysregulation involving the IL-23 pathway. Targeting the IL-23 p19 subunit with monoclonal antibodies offers a more selective approach than earlier therapies targeting the shared p40 subunit. Risankizumab, Mirikizumab, and Guselkumab have been approved for moderate-to-severe IBD, providing new options for advanced therapy. Their differing pharmacologic properties and administration routes necessitate tailored treatment strategies.

Data Highlights

Key Findings

• Anti-IL23p19 agents RIS, MIR, and GUS have demonstrated comparable efficacy and safety in phase 3 trials for moderate-to-severe CD and UC.
• Guselkumab uniquely offers subcutaneous induction, improving patient convenience and reducing infusion-related risks.
• GUS binds CD64 on myeloid cells, potentially enhancing therapeutic effects, though clinical relevance requires further study.
• Selection among anti-IL23p19 therapies should consider patient preference for administration route, IBD phenotype, extra-intestinal manifestations, and prior advanced therapy exposure.
• Anti-IL23p19 inhibitors may become first-line options, especially in patients with IL-23 driven comorbidities like psoriasis.
• Combination therapy with other advanced agents is under investigation to improve outcomes in complex IBD phenotypes.

Clinical Implications

Clinicians should individualize anti-IL23p19 therapy selection based on patient-specific factors including disease characteristics and treatment history. The availability of subcutaneous induction with guselkumab offers a practical alternative to intravenous induction, potentially enhancing adherence and reducing healthcare resource utilization. Monitoring emerging real-world data will further inform optimal positioning of these agents in IBD management.

Conclusion

Selective IL-23p19 inhibitors represent a significant advancement in IBD treatment, offering effective and safe options with varying administration routes and unique properties. Personalized selection of these agents can optimize therapeutic outcomes and patient satisfaction.

References

1. Key Factors in Selecting IL-23p19 Inhibitors for Treating Inflammatory Bowel Disease: Importance and Implications